Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07276386 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Name: Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma — clinical trial record (NCT07276386)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorH. Lee Moffitt Cancer Center and Research Institute

Started2025-12-31

View on ClinicalTrials.gov ↗

Amendment history

2026-03-26

Study Status v1

Start dateestimated 2025-12→confirmed 2025-12-31

2025-12-01

Original filing

H. Lee Moffitt Cancer Center and Research Institute

209 trials monitored

See 17 trials at risk

Melanoma

1,020 trials monitored

See 45 trials at risk

This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances antigen release and immunomodulation, potentially sensitizing tumors to tebentafusp in HLA-A\*02:01-positive patients.

Trial Details

NCT Number	NCT07276386
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: Delcath Systems Inc.
Conditions	Metastatic Uveal Melanoma
Enrollment	18 participants
Start Date	2025-12-31
Primary Completion	2030-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-31